[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clinical-characteristics-and-treatment-outcomes-of-malignant-tumor-cachexia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clinical-characteristics-and-treatment-outcomes-of-malignant-tumor-cachexia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100611653","phase-4-a-prospective-real-world-observational-study-of-nanocrystalline-megestrol-acetate-in-patients-with-cancer-cachexia-100611653",false,"NCT07243379","A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia","Inclusion Criteria:\n\n* Patients with histologically and\u002For cytologically confirmed malignancy.\n* Age ≥18 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and an expected survival of ≥3 months.\n* Meeting the diagnostic criteria for cachexia (based on Fearon's criteria).\n* Body mass index (BMI) ≤30.\n\nExclusion Criteria:\n\n* Presence of any condition affecting gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrolled vomiting; patients receiving tube feeding or parenteral nutrition.\n* Presence of anorexia due to anorexia nervosa, psychiatric disorders, or pain that makes eating difficult.\n* Patients with acquired immunodeficiency syndrome (AIDS).\n* Currently receiving or planning to receive other medications that increase appetite or body weight, such as corticosteroids (except short-term dexamethasone during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.\n* Patients with Cushing's syndrome, adrenal or pituitary insufficiency, or poorly controlled diabetes mellitus.","ALL","18 Years","85 Years",{"count":19,"type":20},495,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.",[26,27],"Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia","Multicenter Observational Study","RECRUITING","2025-11-19",{"date":31,"type":32},"2025-11-21","ACTUAL",{"date":34,"type":32},"2025-09-25",{"date":36,"type":20},"2027-06-30",{"name":38,"class":39},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY"]